RLMD — Relmada Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $297.73m
- $283.85m
Annual income statement for Relmada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 60.8 | 126 | 161 | 104 | 83.9 |
| Operating Profit | -60.8 | -126 | -161 | -104 | -83.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -59.5 | -126 | -157 | -98.8 | -80 |
| Net Income After Taxes | -59.5 | -126 | -157 | -98.8 | -80 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -59.5 | -126 | -157 | -98.8 | -80 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -59.5 | -126 | -157 | -98.8 | -80 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.81 | -7.16 | -5.3 | -3.28 | -2.65 |